Aimmune Therapeutics Inc. (NASDAQ:AIMT) shares were down 4% during trading on Wednesday . The company traded as low as $10.52 and last traded at $10.55, with a volume of 276,506 shares trading hands. The stock had previously closed at $10.99.

A number of research analysts have commented on AIMT shares. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, June 29th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Finally, Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Friday, May 20th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $33.40.

The company’s market cap is $446.13 million. The firm’s 50-day moving average price is $12.74 and its 200-day moving average price is $14.46.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03. On average, analysts forecast that Aimmune Therapeutics Inc. will post ($1.70) earnings per share for the current year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Aisling Capital LLC increased its position in shares of Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares in the last quarter. TLP Group LLC purchased a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $51,314,000. Finally, Alps Advisors Inc. purchased a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $1,027,000.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.